Navigation Links
Possible genetic predictor for response to lithium augmentation in depressed patients
Date:12/6/2007

Philadelphia, PA, December 6, 2007 As in most fields of medicine, psychiatry researchers are working to identify specific types of patients, through their individual genetic variations, that may better benefit from particular drugs or combinations of drugs than other patients. A new study, published in Biological Psychiatrys December 1st issue, investigated whether depressed patients with a particular genetic variation would better respond to the addition of lithium to their treatment regimen, as opposed to an antidepressant-only treatment.

Adli and colleagues recruited acutely depressed patients who were unresponsive to an antidepressant-only treatment, and augmented their therapy with lithium, the most common medication used to treat bipolar disorder. They then genotyped these patients for variations in the GSK3B gene. This gene codes for the enzyme glycogen synthase kinase 3-beta, which is inhibited by lithium. Mazda Adli, M.D., corresponding author on the project, explains their findings: [We] found that antidepressant non-responders with depression show a significantly better response to a subsequent lithium augmentation if they carry at least one C-allele as opposed those patients carrying two T-alleles, which is in line with the previous findings regarding this genetic polymorphism. In other words, patients who carried a specific genetic variation, the C-allele, were more likely to get better with the addition of lithium to their treatment than patients with other variations of the GSK3B gene.

John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments, Over the past several years, preclinical studies have suggested that GSK3-beta was a key molecular switch related to the clinical effectiveness of lithium. This hypothesis is supported by this report from Adli et al. They find that variation in the GSK3-beta gene is related
'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Fairbank Farms Voluntarily Recalls 85% Ground Round Beef Patties Sold Fresh from Shaws Due to Possible Health Risk
2. M.D. Anderson-led team reports possible key to autoimmune disease
3. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
4. Possible safer target for anti-clotting drugs found
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. Why it is impossible for some to just say no
7. Saving Millions of Childrens Lives Is Possible
8. Mayo Clinic Proceedings article explores possible link between obesity and viral infections
9. Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
10. Help for California Fire Evacuees Possible Through Partnership for Prescription Assistance
11. Mayo Clinic study points to a possible biomarker for colon cancer in people 50 and under
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... Kids, parents and schools need to work together t... FRIDAY, Nov. 21 (HealthDay News) -- Behavior that...cognized as bullying. , And as mounting researc... the victim, mental-health professionals, schools,...th new ways to combat this threatening behavior. ...
(Date:11/21/2008)..., HOUSTON(Nov. 21, 2008)The University of Texas He...rogram, Training Excellence in Aging Studies (TEXA...through a prestigious $2 million award from the Do...atching funds., "This will allow us to teach geri...t junior medical student to practicing physicians....
(Date:11/21/2008)... TUCSON, Ariz., Nov. 21 ...C ) today announced that Craig A. Norris, the Comp... to the Company,s Board of,Directors. Mr. Norris...2008,resignation of Steven I. Geringer and return...serve on any committee of the Board. , Mr. ...
(Date:11/21/2008)... Trials showed Banzel proved effective against Len... (HealthDay News) -- A new drug called Banzel (ruf...tment for a severe form of epilepsy called Lennox-...ation announced Friday. , The approval was base...ncluded patients ages 4 to 30. Compared to patient...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...t the Shanghai Children’s Medical Center have succ...rare, well-developed third arm from a two-month-ol...t arms that had been laid across Liu Junjie's ches...is further up his shoulder. ‘We found the nerves ...
... Health Organisation has ruled out human-to-human ...esian nurses tending patients with the disease // ...he ability to spread more readily among humans. 'T...nurses provide reassuring evidence that the virus ...
... drug used to treat chronic myeloid leukemia has s...f patients with the cancer.// The National Institu...h regulates drug approvals in the UK had only want...s, but the drug has not proved itself in clinical ...
...ight is back on drugs and high life in Mumbai with...hospital, and Sahil Zarru, who is suspected to hav...arty circuit here. "Cocaine, ecstasy, acid and her...rugs,are a rage with the rich and the famous in Mu...
Other Medicine News:Health News:Drugs Part of Mumbai High Life 2
(Date:11/21/2008)...England, November 21 , ...an Committee for Medicinal Products for Human Use ...n for the approval of Enbrel(R),(etanercept) as a...,adolescents with severe plaque psoriasis. If appr...mmittee,s recommendation, Enbrel will become the,...
(Date:11/20/2008)... , , PHILADELPHIA, Nov. 20 /PRNewswire-Firs...unced that the United States Food and Drug Adminis...MACTA(R) (eltrombopag) for the treatment of thromb...thic) thrombocytopenic purpura (ITP) who have had ...oglobulins or splenectomy. The approval is a signi...
(Date:11/20/2008)...lif., Nov. 20 Duska Ther...nced today that it has submitted its,pivotal Phas...r a Special,Protocol Assessment (SPA) procedure w..., Subject to securing an agreement with the...tive, double-blind, placebo-controlled and randomi...
(Date:11/19/2008)...O, Nov. 19 Posit Science Corporati...the Society for Neuroscience,Annual Conference in...e,training may benefit Baby Boomers. The compute...m (TM) uses adaptive exercises that target auditor...ed to drive generalized,improvements in cognition...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pregnant mice block out unwelcome admirers to protect their pups 4122 1Pregnant mice block out unwelcome admirers to protect their pups 4122 2Capella University Launches Online PhD Specialization in Nursing Education 24214 1Capella University Launches Online PhD Specialization in Nursing Education 24214 2Capella University Launches Online PhD Specialization in Nursing Education 24214 3Incidence of Mantle Cell Lymphoma on Rise 24211 1Incidence of Mantle Cell Lymphoma on Rise 24211 2Breast Fed Babies Have Fewer GI Infections 24208 1Breast Fed Babies Have Fewer GI Infections 24208 2
...roach to Address Growing Problem of Antibiotic Res...ER, British Columbia, March 26, 2007 /PRNewswire/ ... IDR-1 is the first,immune system trigger to cure ...ccording to a paper published in the April 2007,is...ghlights the work of Inimex and its,co-founders Dr...
...rial Shows CRESTOR Slowed Progression Of Atheroscl...sease , LONDON, March 26, 2006-AstraZeneca today a... is the first study to show a,positive effect on a...id artery disease and at low risk of coronary hear...uvastatin) 40mg and presented at,56th Scientific S...
Other Medicine Technology:Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 3First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 4First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 5
Grafton DBM Matrix PLF is the first bone graft material designed specifically for posterolateral fusion procedures. Unique trough-like design allows for easy use with allograft/autograft bone. Demine
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%.
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%.
Inductive demineralized bone matrix and conductive cancellous chips. DBM and cancellous chips will be free of foreign matter. Demineralized bone matrix particle size is 125 to 1000 . Cancellous chip
Medicine Products: